Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

741

STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/TG4050?src=hash" target="_blank"gt;#TG4050lt;/agt;–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1 clinical trial of its lead myvac™ candidate TG4050 as a potential treatment for ovarian cancer patients after first-line surgery and chemotherapy. TG4050 http://www.businesswire.com/news/home/20190512005008/en/Transgene-receives-FDA-IND-Clearance-Lead-myvac%E2%84%A2/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J